UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported)
May 22, 2014
INOVIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-14888 | 33-0969592 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
1787 Sentry Parkway West Building 18, Suite 400 Blue Bell, Pennsylvania |
19422 | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (267) 440-4200
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07. | Submission of Matters to a Vote of Security Holders. |
Inovio Pharmaceuticals, Inc. (the Company) held its 2014 Annual Meeting of Stockholders on May 22, 2014. The following are the voting results for each matter voted upon:
Proposal 1: The election of the following nominees as directors of the Company to serve until the Companys 2015 Annual Meeting of Stockholders and until their successors are elected.
Name of Director Nominee |
Votes For | Votes Withheld | Broker Non-Votes | |||||||||
Avtar S. Dhillon |
89,491,317 | 14,894,752 | 84,457,987 | |||||||||
J. Joseph Kim |
102,916,581 | 1,469,488 | 84,457,987 | |||||||||
Simon X. Benito |
96,690,704 | 7,705,365 | 84,457,987 | |||||||||
Ángel Cabrera |
102,429,620 | 1,956,449 | 84,457,987 | |||||||||
Morton Collins |
98,778,073 | 5,607,996 | 84,457,987 | |||||||||
Adel A.F. Mahmoud |
98,445,662 | 5,940,407 | 84,457,987 |
Proposal 2: The ratification of Ernst & Young LLP as the Companys independent registered public accounting firm for the year ending December 31, 2014.
For |
Against |
Abstain | ||
183,601,390 | 3,795,702 | 1,446,964 |
Proposal 3: The approval of an amendment to the Certificate of Incorporation of the Company to effect a reverse stock split of the Companys Common Stock at a ratio not less than one-for-two and not greater than one-for-four, with the exact ratio to be set within the range in the discretion of the Board of Directors without further approval or authorization of the Companys stockholders.
For |
Against |
Abstain | ||
124,691,469 | 59,930,580 | 4,222,007 |
Proposal 4: The approval of an amendment to the Companys 2007 Omnibus Incentive Plan (the Plan) to increase the number of shares available for grants under the Plan by 5,000,000 shares and so that all shares authorized for issuance under the Plan be eligible for grants as incentive stock options.
For |
Against |
Abstain |
Broker Non-Votes | |||
77,205,300 | 25,352,457 | 1,828,312 | 84,457,987 |
-2-
Proposal 5: The approval, by non-binding vote, of the compensation of the Companys named executive officers.
For |
Against |
Abstain |
Broker Non-Votes | |||
88,425,581 | 13,036,063 | 2,924,425 | 84,457,987 |
-3-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INOVIO PHARMACEUTICALS, INC. | ||
By: | /s/ Peter Kies | |
Peter Kies, | ||
Chief Financial Officer |
Date: May 22, 2014
-4-